EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals develops and manufactures sustained-release drug delivery products, primarily for ophthalmic conditions. The company’s core business involves the development of pharmaceuticals that are subject to animal testing as part of the regulatory approval process mandated by the FDA and other global health authorities. This reliance on animal testing for product development and safety validation places the company within the scope of commercial animal exploitation.

The company’s operations recently drew regulatory attention. In July 2024, the FDA issued a warning letter to EyePoint citing significant violations of Current Good Manufacturing Practice (CGMP) regulations at its Watertown, Massachusetts facility related to its Yutiq product. While this specific enforcement action addresses manufacturing controls, it underscores the company’s ongoing engagement in the pharmaceutical development pipeline, a process intrinsically dependent on animal testing to bring new therapies to market.